Latest Health Care News

Anagenics Limited has announced a two-tranche placement to raise A$2.25 million, aiming to expand its health and wellness brands while retiring debt and supporting working capital.

Nutritional Growth Solutions (ASX – NGS) has locked in a $2 million capital raise through a share placement aimed at fueling sales, inventory, and growth initiatives, pending shareholder approval.

Nutritional Growth Solutions reported a 13% revenue increase in Q3 FY25, driven by expanded US retail distribution and inventory replenishment. The company raised AU$760k to support growth but faces a tight cash runway, banking on upcoming capital raises and retail momentum.

Holista Colltech has raised $2.295 million through a share placement to two international investors, aiming to bolster its operations and balance sheet. The move highlights the company’s ongoing efforts to support growth across its health and wellness divisions.

Bioxyne Limited reports a remarkable financial turnaround for FY2025, driven by a 217% revenue surge and its first significant profit, underpinned by expanded medicinal cannabis manufacturing and new supply contracts.

Argenica Therapeutics reported a 34% revenue increase driven by R&D incentives but saw losses widen by 31% due to intensified clinical trial activity. The company is progressing its ARG-007 Phase 2 stroke trial and engaging with the FDA to lift a clinical hold.

Nutritional Growth Solutions has completed a $760,000 share placement at a slight discount, aiming to boost inventory and support its retail growth strategy.

Nutritional Growth Solutions revises its Q2 FY25 financials, confirming stable revenue and detailing expanded distribution into CVS and Walmart. The company is actively raising capital to support growth and improve liquidity.

Holista Colltech reported steady customer receipts and a 38% surge in dietary supplement sales for 2QFY25, while progressing its high-value nano-collagen business and refreshing its leadership team.

EVE Health Group has launched a $1.5 million capital raise alongside the acquisition of biotech firm Nextract, aiming to expand its footprint in health and pharmaceutical products focused on erectile dysfunction and period pain.

Anagenics Limited has completed a significant restructuring to simplify operations and issued 35 million shares to FOS Capital as part of this process. The company confirms its going concern status and outlines plans for organic and acquisitive growth over the next year.

Biome Australia Limited has reported its first-ever net profit of $433,395 for the half-year ended December 2024, alongside a 47.4% increase in revenue driven by strong sales of its Activated Probiotics.